https://www.selleckchem.com/products/abt-199.html
The in vitro measured residence time (τR) must be used in concert with equilibrium measures of drug-target affinity (e.g. IC5 and with in vivo measures of pharmacokinetic half-life, to afford the researcher a powerful approach to compound optimization for clinical effect. Despite the significant use and refinement of this model, continued studies are required to better understand the dynamic interplay between residence time, target pathobiology, drug distribution and drug pharmacokinetics.Parkinson's disease (PD) is the second most pr
Like
Comment
Share
